Depressive Disorder, Major
Pipeline by Development Stage
On Market (8)
Approved therapies currently available
Competitive Landscape
14 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 31 trials with date data
Clinical Trials (31)
Total enrollment: 6,592 patients across 31 trials
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Estrogen and Perimenopausal Depression
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Duloxetine in the Treatment of Melancholic Depression
A Study to Test Different Doses of BI 1569912 in People With Depression
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
A Study to Evaluate the Effect of Food on LY2216684
Effectiveness of an Ecological Momentary Emotion Regulation Intervention
Psychoeducational Intervention for Families With a Member Affected by Major Depression
Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation
Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial
European Deep Brain Stimulation (DBS) Depression Study
Deep Brain Stimulation for Major Depressive Disorder